Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 1, p. s511, 2025. DOI: 10.25251/skin.9.supp.511. Disponível em: https://skin.dermsquared.com/skin/article/view/3152. Acesso em: 13 apr. 2025.